squamous cell lung cancer
Conditions
Interventions
Carboplatin plus alternative S-1
Sponsors
Shimane university Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Chemotherapy not enforcement cases of stage IV or stage IIIB clinical stage radical irradiation with a diagnosis of squamous cell carcinoma of the lung biopsy or by cytology is not possible.Patients with measurable disease.Performance Status is 0 or 1.WBC more than 4,000 uL,Neutrocyte more than 1,500/uL,Plate more than 100,000/uL,Hb more than 9.0 g/dL,AST/ALT less than 100 IU/L,Total bilirubin less than 1.5 mg/dL,eGFR more than 40 ml/min./1.73m2,SpO2 more than 94 percent.Cases can be expected survival of more than 12 weeks from the start of the administration date.
Exclusion criteria
Exclusion criteria: Case you are planning to radiation concurrent chemotherapy.In addition, patients who had made every irradiation in 2 weeks.Came into force the definitive operation or cases of enforcement plan.Cases are complicated by serious infections.Patients with brain metastases that have clinical symptoms.Cases with pericardial effusion storage chest or ascites requiring drainage.Patients with pulmonary fibrosis or interstitial pneumonia.Mental illness to be a clinical problem.Patients with overlapping cancer activity.Cases there is a possibility that pregnant women, nursing mothers, pregnant.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Response rate | — |
Secondary
| Measure | Time frame |
|---|---|
| Adverse event, Biomarker, Dose Intensity | — |
Countries
Japan
Contacts
Public ContactKoba Naoya
Shimane university Hospital Division of Medical Oncology & Respiratory Medicine
Outcome results
None listed